Application of Kampo medicines for the palliation of cancer cachexia.


Journal

Neuropeptides
ISSN: 1532-2785
Titre abrégé: Neuropeptides
Pays: Netherlands
ID NLM: 8103156

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 11 04 2021
revised: 18 08 2021
accepted: 19 08 2021
pubmed: 7 9 2021
medline: 26 2 2022
entrez: 6 9 2021
Statut: ppublish

Résumé

Cancer cachexia results in the discontinuation of aggressive cancer therapy, and halting its progression has a significant effect on the survival rate and quality of life of patients with cancer. Currently, there are few therapies to control or slow down the progression of cancer cachexia. Although traditional Japanese Kampo medicine is widely used to support aggressive cancer therapy, the relevant scientific evidence is limited. Additionally, Kampo medicines are based on historical experience. In recent years, there have been widespread attempts to prove the efficacy of Kampo medicines through basic research, and an increasing number of studies have clarified the mechanism of action of Kampo medicines at the molecular level. It has been proposed that the improvement of cancer cachexia by Kampo medicines might involve enhancement of feeding via the central nervous system, improvement of protein maintenance in the skeletal muscle, and suppression of inflammatory cytokine production. In particular, among Kampo medicines, tonifying formulae, called "hozai" in Japanese, have been shown to be effective in alleviating cancer cachexia. In this review, we summarize the recent progress of basic and clinical research in Kampo medicines on cancer cachexia, and introduce Kampo medicines that are expected to be attractive supportive cancer medication.

Identifiants

pubmed: 34488048
pii: S0143-4179(21)00074-3
doi: 10.1016/j.npep.2021.102188
pii:
doi:

Substances chimiques

Cytokines 0
Drugs, Chinese Herbal 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102188

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Masahiro Ohsawa (M)

Department of Neuropharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1, Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan. Electronic address: ohsawa@phar.nagoya-cu.ac.jp.

Toshiaki Makino (T)

Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1, Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.

Yoshiyuki Takimoto (Y)

Department of medical ethics, Graduate School of Medicine, The University of Tkyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Akio Inui (A)

Pharmacological Department of Herbal Medicine, Kagoshima University Graduate School of Medical & Dental Sciences, 8-35-1, Sakuraga-oka, Kagoshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH